Actinium Pharmaceuticals

Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.
Company Growth (employees)
New York, US
Size (employees)
23 (est)
Actinium Pharmaceuticals was founded in 2000 and is headquartered in New York, US

Actinium Pharmaceuticals Office Locations

Actinium Pharmaceuticals has an office in New York
New York, US (HQ)
275 Madison Ave

Actinium Pharmaceuticals Financials and Metrics

Actinium Pharmaceuticals Financials


Net income (Q2, 2017)

(7.1 m)

EBIT (Q2, 2017)

(7.2 m)

Market capitalization (08-Dec-2017)

50.8 m

Cash (30-Jun-2017)

11.5 m
Actinium Pharmaceuticals's current market capitalization is $50.8 m.
USDFY, 2014FY, 2016

R&D expense

12.3 m

General and administrative expense

10.2 m9.3 m

Operating expense total

22.4 m9.3 m


(22.5 m)(26.8 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

General and administrative expense

830.7 k1.7 m2.4 m3.3 m3.8 m3.6 m1.8 m2.2 m2.8 m1.4 m3.3 m2.8 m

Operating expense total

1.6 m4.1 m4.4 m7 m7.9 m7.4 m4.6 m6 m6.9 m7.1 m7.8 m7.2 m


(1.6 m)(4.1 m)(4.4 m)(7 m)(7.9 m)(7.4 m)(4.6 m)(6 m)(6.9 m)(7.1 m)(7.8 m)(7.2 m)

Interest expense

1.3 k5.7 k1.6 k5882.7 k1.7 k666
USDFY, 2013FY, 2014FY, 2015FY, 2016


5.5 m6.7 m25.6 m20.5 m

Accounts Receivable

2.1 b


218.4 k699.9 k803.5 k1.8 m

Current Assets

5.8 m7.4 m26.5 m22.4 m
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


26 m24.8 m22.2 m20.5 m15.5 m17.1 m11.5 m

Current Assets

26.2 m24.9 m23.2 m21.4 m17.1 m18.1 m12.5 m


86.2 k95.3 k115.6 k110 k91.2 k75.9 k70 k

Total Assets

26.3 m25 m23.3 m21.6 m17.3 m18.2 m13 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(10.8 m)(24.7 m)(21 m)(24.3 m)

Depreciation and Amortization

1.6 k37.9 k53.5 k77.5 k


106.6 k(193.9 k)162.1 k(1 m)

Accounts Payable

(793.9 k)2.7 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(4.9 m)(16.7 m)(13.2 m)(19.3 m)(3.1 m)(10.5 m)(14.5 m)(4.4 m)(11 m)(17.6 m)(8.1 m)(15.1 m)

Depreciation and Amortization

1.4 k9.5 k23.8 k10.4 k26.6 k43.4 k18.1 k37.6 k57.7 k20.9 k35.3 k

Accounts Payable

236.3 k666.5 k1.4 m(1 m)(1.3 m)(1.4 m)378.9 k(94.8 k)1.1 m573.9 k(590.3 k)

Cash From Operating Activities

(4.9 m)(2.5 m)(5.1 m)(9.3 m)(5.8 m)(11.1 m)(14.6 m)(4.8 m)(11 m)(16.5 m)(5.4 m)(12.5 m)
Y, 2017

Financial Leverage

1.5 x
Show all financial metrics

Actinium Pharmaceuticals Market Value History

Actinium Pharmaceuticals's Web-traffic and Trends

Actinium Pharmaceuticals Online and Social Media Presence

Actinium Pharmaceuticals Company Life and Culture

You may also be interested in